Beyond the Stent (“Leave-Nothing-Behind”) Drug-Coated Balloons in Acute Coronary Syndrome: A Narrative Review
Open Access
- 10 June 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4491
Abstract
Background: Drug-coated balloons (DCBs) have emerged as a “leave-nothing-behind” strategy in percutaneous coronary intervention (PCI), with potential advantages over drug-eluting stents (DES) in selected patients with acute coronary syndrome (ACS). Methods: We performed a narrative review of randomized controlled trials, registries, and meta-analyses evaluating DCB therapy in ACS, including PEPCAD NSTEMI, REVELATION, BASKET-SMALL 2, AGENT IDE, REC-CAGEFREE I/II, and the ongoing TRANSFORM II trial. Articles were identified through searches of PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane CENTRAL covering January 2005 to February 2026. Results: Across published studies, DCBs have shown outcomes that are non-inferior to those of DES in selected ACS subsets, together with a lower risk of major bleeding attributable to shorter dual antiplatelet therapy (DAPT) requirements. Advances in intravascular imaging and lesion preparation, alongside emerging applications of artificial intelligence (AI) and robotic-assisted PCI, may further improve DCB performance, although evidence specific to DCB use in ACS remains limited for these adjunctive technologies. Conclusions: DCBs are a reasonable alternative to DES in selected patients with ACS, particularly those at high bleeding risk or with lesion subsets in which DES perform less well (small vessels, in-stent restenosis, bifurcations, diffuse disease). Adequately powered randomized trials with long-term follow-up are required before broader recommendations can be made.Keywords
All Related Versions
This publication has 61 references indexed in Scilit:
- Drug‐Coated Balloons in Coronary Artery Disease: Engineering, Pharmacology, and the Mechanisms Behind Angiographic OutcomesCatheterization and Cardiovascular Interventions, 2026
- One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE RegistryAmerican Journal of Cardiovascular Drugs, 2025
- A Meta-Analysis of 3-Year Outcomes of Drug-Coated Balloons Versus Drug-Eluting Stents for Small-Vessel Coronary Artery DiseaseJACC: Advances, 2024
- Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent RestenosisJAMA, 2024
- Sirolimus‐coated balloon versus everolimus‐eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trialCatheterization and Cardiovascular Interventions, 2022
- Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplastyClinical Research in Cardiology, 2014
- Treatment of coronary de novo bifurcation lesions with DCB only strategyClinical Research in Cardiology, 2014
- First Results of the DEB-AMI (Drug Eluting Balloon in Acute ST-Segment Elevation Myocardial Infarction) TrialJACC, 2012
- Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis modelClinical Research in Cardiology, 2009
- Pathology of Drug-Eluting Stents in HumansJACC, 2006